{"doi":"10.1128/aac.00751-24","title":"ARGONAUT-III and -V: susceptibility of carbapenem-resistant <i>Klebsiella pneumoniae</i> and multidrug-resistant <i>Pseudomonas aeruginosa</i> to the bicyclic boronate β-lactamase inhibitor taniborbactam combined with cefepime","abstract":"ABSTRACT Taniborbactam, a bicyclic boronate β-lactamase inhibitor with activity against Klebsiella pneumoniae carbapenemase (KPC), Verona integron–encoded metallo-β-lactamase (VIM), New Delhi metallo-β-lactamase (NDM), extended-spectrum beta-lactamases (ESBLs), OXA-48, and AmpC β-lactamases, is under clinical development in combination with cefepime. Susceptibility of 200 previously characterized carbapenem-resistant K. pneumoniae and 197 multidrug-resistant (MDR) Pseudomonas aeruginosa to cefepime-taniborbactam and comparators was determined by broth microdilution. For K. pneumoniae (192 KPC; 7 OXA-48-related), MIC 90 values of β-lactam components for cefepime-taniborbactam, ceftazidime-avibactam, and meropenem-vaborbactam were 2, 2, and 1 mg/L, respectively. For cefepime-taniborbactam, 100% and 99.5% of isolates of K. pneumoniae were inhibited at ≤16 mg/L and ≤8 mg/L, respectively, while 98.0% and 95.5% of isolates were susceptible to ceftazidime-avibactam and meropenem-vaborbactam, respectively. For P. aeruginosa , MIC 90 values of β-lactam components of cefepime-taniborbactam, ceftazidime-avibactam, ceftolozane-tazobactam, and meropenem-vaborbactam were 16, &gt;8, &gt;8, and &gt;4 mg/L, respectively. Of 89 carbapenem-susceptible isolates, 100% were susceptible to ceftolozane-tazobactam, ceftazidime-avibactam, and cefepime-taniborbactam at ≤8 mg/L. Of 73 carbapenem-intermediate/resistant P. aeruginosa isolates without carbapenemases, 87.7% were susceptible to ceftolozane-tazobactam, 79.5% to ceftazidime-avibactam, and 95.9% and 83.6% to cefepime-taniborbactam at ≤16 mg/L and ≤8 mg/L, respectively. Cefepime-taniborbactam at ≤16 mg/L and ≤8 mg/L, respectively, was active against 73.3% and 46.7% of 15 VIM- and 60.0% and 35.0% of 20 KPC-producing P. aeruginosa isolates. Of all 108 carbapenem-intermediate/resistant P. aeruginosa isolates, cefepime-taniborbactam was active against 86.1% and 69.4% at ≤16 mg/L and ≤8 mg/L, respectively, compared to 59.3% for ceftolozane-tazobactam and 63.0% for ceftazidime-avibactam. Cefepime-taniborbactam had in vitro activity comparable to ceftazidime-avibactam and greater than meropenem-vaborbactam against carbapenem-resistant K. pneumoniae and carbapenem-intermediate/resistant MDR P. aeruginosa .","journal":"Antimicrobial Agents and Chemotherapy","year":2024,"id":433258,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":14,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9577,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1238987,"name":"Ayman M. Abdelhamed","orcid":null,"position":1,"is_corresponding":false},{"id":619530,"name":"Caryn E. Good","orcid":null,"position":2,"is_corresponding":false},{"id":270506,"name":"Andrew R Mack","orcid":"0000-0002-0131-7996","position":3,"is_corresponding":false},{"id":384425,"name":"Christopher R. Bethel","orcid":null,"position":4,"is_corresponding":false},{"id":594792,"name":"Steven H. Marshall","orcid":"0009-0003-1811-2633","position":5,"is_corresponding":false},{"id":232749,"name":"Andrea M. Hujer","orcid":"0009-0001-3543-1826","position":6,"is_corresponding":false},{"id":234484,"name":"Kristine M. Hujer","orcid":null,"position":7,"is_corresponding":false},{"id":232756,"name":"Robin Patel","orcid":"0000-0001-6344-4141","position":8,"is_corresponding":false},{"id":232741,"name":"David van Duin","orcid":"0000-0003-4784-3227","position":9,"is_corresponding":false},{"id":32929,"name":"Vance G. Fowler","orcid":"0000-0002-8048-0897","position":10,"is_corresponding":false},{"id":685221,"name":"Daniel D. Rhoads","orcid":"0000-0002-7636-5191","position":11,"is_corresponding":false},{"id":887202,"name":"David A. Six","orcid":"0000-0002-9013-1711","position":12,"is_corresponding":false},{"id":666474,"name":"Greg Moeck","orcid":"0000-0001-7827-7227","position":13,"is_corresponding":false},{"id":1218567,"name":"Tsuyoshi Uehara","orcid":"0000-0001-6994-4286","position":14,"is_corresponding":false},{"id":270505,"name":"Krisztina M. Papp‐Wallace","orcid":"0000-0002-9976-7898","position":15,"is_corresponding":false},{"id":232761,"name":"Robert A. Bonomo","orcid":"0000-0002-3299-894X","position":16,"is_corresponding":false},{"id":491853,"name":"Michael R. Jacobs","orcid":"0000-0002-4235-7855","position":0,"is_corresponding":true}],"reference_count":26,"raw_metadata":null,"created_at":"2026-07-19T01:59:44.444627Z","pmid":"39133021","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}